Prognostics and Clinical Outcomes in Patients Diagnosed With Acute Myeloid Leukemia (AML) in a Teaching Hospital

Hind A. Alsulami 1, Maryam M. Alnashri 1, Alanoud F. Bawazir 1, Laila T. Alrashid 1, Raghdah A. Dly 1, Yusr A. Alharbi 1, Mohamad H. Qari 1

1. Hematology Department, King Abdulaziz University Hospital, Jeddah, SAU

Corresponding author: Hind A. Alsulami, h.alsulami24@gmail.com

Abstract

Background: Acute myeloid leukemia (AML) is a heterogeneous disease. Prognosis and survival depend on several factors that determine tumor behavior and response to therapy. AML has a poor prognosis that depends on several factors: patient’s age, gender, body mass index (BMI), baseline white blood cells count, and bone marrow blast (BMB) cell count at the time of diagnosis. Therefore, this study aimed to determine the prognostic role of these factors and their impact on outcomes, and how these prognostic factors may affect AML patients before and after induction chemotherapy.

Methods: The study design is an observational, retrospective record review. We included records of patients diagnosed with primary and secondary AML who received chemotherapy between 2015 and 2019 at King Abdulaziz University in Jeddah, Saudi Arabia. Data were extracted from medical records, entered into an Excel sheet (Microsoft Corp., Redmond, WA), and analyzed using SPSS Statistics, version 25 (IBM Corp., Armonk, NY).

Results: Forty-two AML patients who were started on chemotherapy were analyzed. The mean age at diagnosis was 35 ± 22.2 years; 52.4% were male. The ability to achieve the first remission varied according to age group: the 21-45 age group had the higher ability and survival rate of 75.0%. On the other hand, the mortality incidence was higher (at 70.0%) in both the 11-20 and the 46-70 age groups. A strong negative correlation was observed between age and survival duration after treatment (SDAT) (r = -0.618, p = 0.004). The death incidence was increased in the BMI ranges that were under and above the normal weight range. SDAT differed significantly between the three groups in favor of the normal-weight patients (p = 0.019). We found that patients with BMB < 5 had the most deaths. There was a significant negative association between BMB and days to achieve the first remission after treatment (p = 0.033).

Conclusion: Age, BMI, and BMB are considered effective prognostic factors for AML patients.

Introduction

Acute myeloid leukemia (AML) is a malignant hematological disease characterized by the infiltration of the bone marrow, blood, and other tissues through clonal expansion and poorly differentiated cells of the hematopoietic system [1]. AML accounts for the largest number of deaths in leukemia patients in the United States [1]. It affects bone marrow (BM) stem cells, specifically, the myeloid cells resulting in a higher increase in myeloid blasts number (the immature form) and arresting the maturation of these blasts [2,3]. These nonfunctional cells will cause hematopoietic dysfunction resulting in potential decreases in other blood cells, including red blood cells (RBCs), white blood cells (WBCs), platelets (PLTs) [2,3].

According to the WHO, detecting more than 20% of BM cells as myeloid blasts is diagnostic for AML [3]. The real causes of AML have not been identified explicitly so far. According to the American Cancer Society, there are many risk factors for AML including age (mainly in adults) and sex (it is the third most common malignancy affecting males and the fifth in females) [4]. In addition, other factors include smoking, chemotherapy exposure for other malignancy treatment, being exposed to certain chemicals or radiation, and having a genetic syndrome or mutation [5,6]. The typical treatment for most types of AML is chemotherapy, sometimes combined with a targeted therapy drug [6]. This might be followed by a stem cell transplant, surgery, or radiation therapy [6].

Several variables have been reported as prognostic factors, including age, sex, and body mass index (BMI) with different clinical outcomes [7-10]. The backbone therapy for AML is intensive chemotherapy regimens such as cytarabine and an anthracycline (7 + 3 regimen), with a complete remission average of 60%-80% in younger adults and decreased efficiency in the elderly who are above 60 years old, with full
Nineteen (45.2%) patients were still alive at the end of the study (13th April 2019), with a mean survival of patients. The median SDAT was 26 days, IQR = 194, with a minimum of 0 days and a maximum of 901 days. For four of them, and thus, the survival duration after treatment (SDAT) was accounted for the remaining 19 was achieved by 22 patients (52.4%) with an elapsed duration average of 74 ± 49.6 days; 54.5% of these blood types were O+ (16, 39%) and A+ (13, 31.7%). Reaching the first remission after chemotherapy induction the population size and percentage follow-up at the hospital. Thus, 42 patients were analyzed to explore the prognostics and clinical outcomes. Forty-six patients were diagnosed with AML and had chemotherapy induction in the hospital from 2013 to 2019. Four were excluded due to incomplete data regarding chemotherapy induction or not completing the disease, the efficacy of treatment, and even the type of treatment that should be used. Our study aimed to investigate AML prognostic factors including age, sex, BMI, RBCs, WBCs, and PLT count, in addition to BMB and PBB factors, and to evaluate the chemotherapy response of patients in King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia.

Materials And Methods
This study is a retrospective record review which was conducted by reviewing all AML patients’ records and including those who were on chemotherapy from 2013 to 2019, at King Abdulaziz University Hospital, Jeddah, Saudi Arabia. It was approved by the Unit of Biomedical Ethics at King Abdulaziz University Faculty of Medicine (Reference No. 459-21). Demographic data were scanned (sex, age, BMI, and blood type), the examined prognostics were baseline white blood cells (WBCs), red blood cells (RBCs), platelets (PLTs), peripheral blood blast (PBB), bone marrow blast (BMB) counts in addition to age and BMI. The data were correlated with the following outcomes: an initial remission after chemotherapy induction, the duration required to achieve it, mortality, and the survival duration after treatment (SDAT) until the patient’s death or the end of study follow-up. The following normal laboratory values were used as reference for the tested parameters: BMI, 18.5-24.9 kg/m^2; WBC, 4.5-11 × 10^9/L; PBB, 0%; BMB, ≤ 5%; RBC, 4-6 million cells/µL; platelets, 150-450 × 10^3 platelets/µL. Data were entered into an Excel sheet (Microsoft Corp., Redmond, WA) and analyzed using SPSS Statistics, version 25 (IBM Corp., Armonk, NY). The statistical analyses used for univariate qualitative and quantitative data were frequency and measure of central tendencies (MCTs), respectively. We used the following tests for bivariate qualitatives and/or normally-distributed quantitative comparison: Chi-square test, independent samples t-test, one-way analysis of variance (ANOVA), and Pearson correlation. Mann Whitney U test, Kruskal Wallis H test, and Spearman correlation were used to test non-normally distributed quantitative (survival duration after treatment, RBC, and platelets count) and qualitative data. P-value < 0.05 was considered significant.

Results
Forty-six patients were diagnosed with AML and had chemotherapy induction in the hospital from 2013 to 2019. Four were excluded due to incomplete data regarding chemotherapy induction or not completing the follow-up at the hospital. Thus, 42 patients were analyzed to explore the prognostics and clinical outcomes.

The population size and percentage
The mean age at diagnosis was 35 ± 22 years old. Twenty-two patients were male (52.4%). The most frequent blood types were O+ (16, 39%) and A+ (13, 31.7%). Reaching the first remission after chemotherapy induction was achieved by 22 patients (52.4%) with an elapsed duration average of 74 ± 49.6 days; 54.5% of these patients were still alive. Of the total 42 patients, 25 (54.8%) died, but the date of death was not documented for four of them, and thus, the survival duration after treatment (SDAT) was accounted for the remaining 19 patients. The median SDAT was 26 days, IQR = 194, with a minimum of 0 days and a maximum of 901 days. Nineteen (45.2%) patients were still alive at the end of the study (13th April 2019), with a mean survival of 946 days. Regarding AML types and survival, 28 (66.7%) had primary AML, including two (7.1%) who had
experienced previous chemotherapy, and 16 (57%) were still alive. Of the 14 patients (33.3%) who had secondary AML, three (21.4%) have survived (P = 0.028).

**BMI at diagnosis**

The death incidence was increased in the BMI ranges that were under and above the normal range. Of the total deaths, six patients had underweight BMI, seven patients had normal BMI, and 10 patients had overweight BMI, but the difference was not significant (P = 0.110). The SDAT was significantly different between the three groups favorably to the normal-weight patients (P = 0.019); the median was 446 days for underweight (n=3), 27 days for normal weight (n=7), and 18 days for overweight (n=9).

**Age at diagnosis**

The ability to reach the first remission has been found to be varied among age groups. Patients aged 21-45 years showed the best ability to get the remission. Regarding mortality, the incidence was higher (at 70.0%) in both the 11-20 and 46-70 age groups, while survival was higher in the 21-45 group at 75.0% (Table 1). Moreover, a strong negative correlation was observed between age and the SDAT (r = -0.618, P = 0.004).

| Prognostic Factor at Diagnosis, N | Mortality N (%) | P-value |
|----------------------------------|----------------|---------|
| **Body Mass Index, 42**          |                |         |
| Normal weight, 18                | 7 (38.9%)      | 0.110   |
| Overweight, 13                   | 10 (76.9%)     | 0.110   |
| Underweight, 11                  | 6 (54.5%)      | 0.110   |
| **Age groups, 42**               |                |         |
| (0 – 10), 6                      | 3 (50.0%)      | 0.142   |
| (11 – 20), 10                    | 7 (70.0%)      | 0.142   |
| (21 – 45), 12                    | 3 (25.0%)      | 0.142   |
| (46 – 70), 10                    | 7 (70.0%)      | 0.142   |
| (> 70), 4                        | 3 (75.0%)      | 0.142   |
| **Wight Blood Cells, 42**        |                |         |
| Normal, 4                        | 2 (50.0%)      | 0.726   |
| High, 27                         | 16 (59.3%)     | 0.726   |
| Low, 11                          | 5 (45.5%)      | 0.726   |
| **Bone Marrow Blast, 33**        |                |         |
| (5 – 19%), 8                     | 4 (50%)        | 0.169   |
| (< 5%), 7                        | 6 (85.7%)      | 0.169   |
| (>= 20%), 18                     | 8 (44.4%)      | 0.169   |
| **Peripheral Blood Blast, 39**   |                |         |
| (< 20%), 8                       | 3 (37.5%)      | 0.163   |
| (>= 20%), 31                     | 20 (64.5%)     | 0.163   |

**TABLE 1: Prognostic factors prediction in AML patients**

N = total number.

**WBC at diagnosis**

We noted that the death rate tended to be increased in patients with high WBC (P = 0.726).
BMB at diagnosis
Out of 42 patients, nine patients' data was missed. We found patients with BMB < 5% had the highest death events, and the incidence decreased as the BMB increased (Table 7). There was a significant adverse relationship between BMB and the days elapsed until reaching the initial remission after treatment; the longest duration was observed in BMB < 5% with an average of 134 days, 95% CI (83 to 185.6), (P = 0.033).

PBB at diagnosis
Out of 39 patients, it was found that as PBB increased at diagnosis, so did the death events. This trend was opposite to the one seen for BMB at diagnosis.

The results did not show a notable prognostic trend for RBCs and platelet count, although the median at diagnosis date was low (3, 51), respectively.

Discussion
A comprehensive understanding of AML is required to treat patients appropriately. Consequently, we evaluated the role of several prognostics with certain outcomes spontaneously in the same population since the disease is influenced by the genome and the genetic expression status and might vary in different regions or cultures [18].

Body mass index is a number that reflects the body weight-adjusted to height. Normal values are 18.5-24.9 kg/m^2. while 25-29.9 kg/m^2 are considered overweight [19]. Recent studies have marked out the effect of BMI on the outcome of AML patients' treatment. A study reported that children with normal body weight have better outcomes compared with overweight and underweight patients, which confirms our findings [19]. Although multiple reports show the relationships between adult AML patients' body mass index and the clinical outcomes, they only studied overweight status [20-23]; other studies showed that underweight patients get poorer outcomes compared with normal-weight patients [24]. In the present study, underweight and overweight patients showed poorer clinical outcomes; they had higher death incidence compared with normal-weight patients.

As is known about the age prognosis effect, aging is a poor prognostic from several aspects [7]. The finding suggests that as patients get older, they will experience an unfavorable prognosis since the survival duration after treatment decreases; patients aged 65 years or older have a dismal prognosis even after intensive chemotherapy, irrespective of their cytogenetic risk [25]. Moreover, younger patients reached the first remission at a higher percentage than older patients. This may be because of the increase of chromosomal abnormalities associated with the disease as a person gets older [7]. Older patients may additionally have other health problems that make it difficult for them to deal with the side effects of treatments for AML.

Our results indicate that there is a trend toward a poor prognostic role for WBC. As WBC increases, from a WBC interval to another higher one, the death rate increases by approximately 6%. It is not significant, but a study in Iran supported the assumption [2]. However, a study in France found no significant impact of WBC count on reaching complete remission (CR); the WBC index as a prognostic factor (WBC*BMB/100) showed a strong negative prognosis for overall survival and disease-free survival, p-value = 0.002 [15]. We suggest that these differences between the studies, especially between previous studies and ours are due to the different populations and the small sample size compared with the other studies (42 vs. 96 and 154, respectively) [2,15].

Our results suggest that the increased BMB count mainly has a negative effect on survival. On the one hand, BMB was not a parameter of concern at diagnosis, as many of our patients were diagnosed with AML without considering bone marrow aspiration. On the other hand, almost all our patients had documented blood film for PBB count at diagnosis, which showed that a PBB of more than 20% was associated with higher mortality, reflecting its importance in disease progression. However, our finding supports a study comparing BMB and PBB in the evaluation of AML where the authors found that both BMB and PBB can be used for diagnosis and mainly PBB for monitoring AML patients [26]. In addition, there was an unobvious impact for RBCs and platelets. We did not find a study to compare our result for RBC and platelets, which did not show any notable role.

Several factors limited the study. Though the study involved all AML patients in the hospital between 2013 and 2019, the sample size was relatively small, and the documentation was incomplete in some cases. Also, the absence of measurements of certain variables held us from conducting the study more comprehensively. For those factors (platelets, RBC, and sex) that did not show significant influence, a study with a higher sample size is recommended to confirm their impact on our population. It should be in multicenter to reach a larger population that involves most existing races and conditions.

Conclusions
AML is considered a devastating disease characterized by a variety of recurring gene mutations. This study
aimed to check how prognostic factors affect patients with AML before and after chemotherapy induction. We found that age, BMI, BMB were the more effective prognostic factors, followed by PBB and then WBCs. Our data indicated that BMB and PBB have inverse roles with mortality. It is suggested that patients’ age at diagnosis is the strongest patient-related prognostic factor. However, we didn’t find any significant impact of WBCs on AML patients. To gain new insights for future studies, we recommend other authors consider more laboratory data such as cytogenetic and gene mutation data.

### Additional Information

#### Disclosures

**Human subjects:** Consent was obtained or waived by all participants in this study. Unit of Biomedical Ethics at King Abdulaziz University Faculty of Medicine issued approval (Reference No. 439-21). **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

### References

1. Tallman MS, Wang ES, Altman JK, et al.: Acute myeloid leukemia, version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019, 17:721-49. 10.6004/jnccn.2019.0028
2. Allahyari A, Tajeri T, Sadeghi M: Prognostic factors and survival in acute myeloid leukemia cases: a report from the Northeast of Iran. Asian Pac J Cancer Prev. 2016, 17:1547-51. 10.7314/apcp.2016.17.5.1547
3. Al-Qusei A, Al-Akhras M, Al-Hajj M, et al.: Clinical features and outcome of acute myeloid leukemia, a single institution experience in Saudi Arabia. J Appl Hematol. 2015, 6:6-12. 10.4103/1658-5127.155171
4. Braas J: Acute myeloid leukemia. (Article in German). Dtsch Med Wochenschr. 2016, 141:1748-53. 10.1055/s-0042-1732055
5. Belson M, Kingsley B, Holmes A: Risk factors for acute leukemia in children: a review. Environ Health Perspect. 2007, 115:138-45. 10.1289/ehp.9023
6. Deschler B, Lübbert M: Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006, 107:2099-107. 10.1002/cncr.22253
7. Appelbaum FR, Grundaker H, Head DR, et al.: Age and acute myeloid leukemia. Blood. 2006, 107:5481-5. 10.1182/blood-2005-09-3724
8. Lehmann DJ, Abrahamsson J, Ha SY, et al.: Effect of age and body weight on toxicity and survival in pediatric acute myeloid leukemia: results from NOPHO-AML 2004. Haematologica. 2016, 101:1559-67. 10.3324/haematol.2016.146175
9. Aoki J, Kanamori H, Tanaka M, et al.: Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia. Am J Hematol. 2016, 91:502-7. 10.1002/ajh.24270
10. Chorós PA, Tavares NT, Aguiar E, Amarim ML, Gomes P, Principe F, Guimaraes IE: Prognostic factors of clinical use in acute myeloid leukemia. Ann Oncol. 2018, 29:viii366. 10.1093/annonc/mdy286.022
11. Bell JA, Galaznik A, Farrell E, et al.: A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent. Leuk Res. 2019, 78:45-51. 10.1016/j.leukres.2019.01.008
12. Schiffer CA: ‘I am older, not elderly,’ said the patient with acute myeloid leukemia . J Clin Oncol. 2010, 28:521-3. 10.1200/JCO.2009.25.8616
13. Döhner H, Weisdorf DJ, Bloomfield CD: Acute myeloid leukemia . N Engl J Med. 2015, 373:1136-52. 10.1056/NEJMra1406184
14. Jahic A, Iljazić E, Hasic S, et al.: Prognostic parameters of acute myeloid leukaemia at presentation . Med Arch. 2017, 71:20-4. 10.5455/medarh.2017.71.20-24
15. Nguyen S, Leblanc T, Fenaux P, et al.: A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Leukemia. 2005, 19:1567-72. 10.1038/sj.leu.2403876
16. Marcucci G, Molérez K, Ruppert AS, et al.: Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005, 23:5705-17. 10.1200/JCO.2005.15.610
17. Masseti R, Vendemini F, Zama D, Biagi C, Pession A, Locatelli F: Acute myeloid leukemia in infants: biology and treatment. Front Pediatr. 2015, 3:57. 10.3389/fped.2015.00057
18. Lange BJ, Gerbing RB, Feunzer J, Skolnik J, Sacks N, Smith FO, Alonzo TA: Mortality in overweight and underweignt children with acute myeloid leukemia. JAMA. 2005, 293:205-11. 10.1001/jama.293.2.205
19. Crysandt M, Kramer M, Ehninger G, et al.: A high BMI is a risk factor in younger patients with de novo acute myelogenous leukemia. Eur J Haematol. 2016, 97:17-24. 10.1111/ejh.12675
20. Medeiros BC, Othu M, Estey EH, Fang M, Appelbaum FR: Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. Haematologica. 2012, 97:1401-4. 10.3324/haematol.2011.056590
21. Taviani S, Denis A, Verges F, et al.: Impact of obesity in favorable-risk AML patients receiving intensive
23. Wenzell CM, Gallagher EM, Earl M, et al.: Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight. Am J Hematol. 2015, 88:906-9. 10.1002/ajh.23550

24. Harada K, Doki N, Hagino T, et al.: Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201. Ann Hematol. 2018, 97:73-81. 10.1007/s00277-017-3156-x

25. Liersch R, Müller-Tidow C, Berdel WE, Krug U: Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use. Br J Haematol. 2014, 165:17-38. 10.1111/bjh.12750

26. Percival ME, Lai C, Estey E, Hourigan CS: Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. Blood Rev. 2017, 31:185-92. 10.1016/j.blre.2017.01.003